Cristiana Mayer
Janssen (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Hepatitis C virus research, Hepatitis B Virus Studies, Health Systems, Economic Evaluations, Quality of Life, Statistical Methods in Clinical Trials
Most-Cited Works
- → Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies(2014)135 cited
- → Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy(2014)116 cited
- → Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results(2014)95 cited
- → Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies(2014)86 cited
- → Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial(2023)69 cited
- → JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2(2024)39 cited
- → Simulation Practices for Adaptive Trial Designs in Drug and Device Development(2019)27 cited
- → Advancing innovative clinical trials to efficiently deliver medicines to patients(2022)16 cited
- → Survey Results on Industry Practices and Challenges in Subgroup Analysis in Clinical Trials(2015)15 cited
- → Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study(2022)14 cited